NCT04282980Phase 2Completed

A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)

Study sponsor: Zai Lab (Shanghai) Co., Ltd.

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2021-02-26Actual

Enrollment · participants39Actual

Source updated2025-03-03Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Gastrointestinal Stromal Tumors

Treatments or interventions studied

DCC-2618DrugAlso known as Ripretinib

Primary outcomes · main study measures

measure: Progression-Free Survival (PFS); description: Progression-Free Survival (PFS) is defined as the time from the first dose of study drug to the first occurrence of disease progression based on independent radiology review or death due to any cause (whichever occurred first).; timeFrame: Approximately 10 months since the first subject enrolled.

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history